Else Nutrition (BABY) Q4 2024 earnings summary

Executive summary

• 2024 was marked by significant challenges, including funding constraints, limited marketing budgets, and inventory shortages, prompting decisive cost-cutting and operational optimization.

• Strategic actions included reducing overhead, cutting underperforming roles, exiting unprofitable retail partnerships, and securing alternative funding to safeguard long-term business viability.

• Expansion into new markets and product categories, such as adult nutrition, and increased retail and e-commerce distribution were key focus areas.

• Restructured R&D, closed Israel lab, and consolidated innovation efforts to improve financial performance.

• Advocacy efforts continue for regulatory modernization of plant-based infant formula, aligning with FDA's Operation Stork Speed.

Financial highlights

• Revenue for 2024 was CAD 8 million, down 14.8% from CAD 9.4 million in 2023.

• Gross loss for 2024 was CAD 1.2 million, compared to CAD 0.1 million in 2023.

• Inventory write-downs in 2024 totaled CAD 2.2 million; excluding this, gross profit would have been CAD 1.1 million (13% margin).

• Operating expenses decreased by 20% to CAD 13.6 million from CAD 16.9 million in 2023.

• Cash balance as of December 31, 2024, was CAD 0.3 million, including restricted cash.

Outlook and guidance

• Priorities for 2025 include expanding retail distribution, scaling European production, and enhancing brand visibility through targeted marketing.

• Focus on strategic partnerships and new product launches to drive long-term growth.

• Expectation of improved product margins, higher revenues, and resolution of inventory issues as funding stabilizes.